Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Apple Turns 50: From Garage Startup to AI Crossroads 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
WALTHAM, Mass., Jan. 06, 2017 -- Radius Health, Inc. (Nasdaq:RDUS), a science-driven biopharmaceutical company focused on developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, today announced that President and Chief Executive Officer, Robert E. Ward, will present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017 at 11:00 a.m. PST at the Westin St. Francis Hotel in San Francisco, California.
The Company's presentation will be webcast live on the Company's website at www.radiuspharm.com, and a replay will be available there following the presentation. The Company will also post a copy of the presentation materials on its website, www.radiuspharm.com.
About Radius
Radius is a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases. Radius' lead product candidate, the investigational drug abaloparatide for subcutaneous injection, has completed Phase 3 development for potential use in the reduction of fracture risk in postmenopausal women with osteoporosis. Radius' Marketing Authorisation Application (MAA) for abaloparatide-SC for the treatment of postmenopausal women with osteoporosis is under regulatory review in Europe and a New Drug Application (NDA) has been accepted for filing by the FDA with a PDUFA date of March 30, 2017. The Radius clinical pipeline also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women. Radius' preclinical pipeline includes RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in cancer. For more information, please visit www.radiuspharm.com
Investor Relations Contact: Barbara Ryan Email: [email protected] Phone: 203-274-2825 Media Contact: Lori Gorski Email: [email protected] Phone: 617-551-4096
